ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03020966
Previous Study | Return to List | Next Study

IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty (IV Tylenol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03020966
Recruitment Status : Recruiting
First Posted : January 13, 2017
Last Update Posted : March 29, 2018
Sponsor:
Collaborator:
Mallinckrodt
Information provided by (Responsible Party):
Hospital for Special Surgery, New York

Brief Summary:
The purpose of this study is to determine how well two different methods of administrating Tylenol reduce pain and improve patient satisfaction after total hip replacement (THR) surgery. The methods of administration are orally, via a pill that is to be swallowed, and intravenously. Our aim is to determine whether oral or intravenous administration of Tylenol will reduce opioid consumption and opioid-related side effects after THR.

Condition or disease Intervention/treatment Phase
Pain, Postoperative Opioid Use Drug: Acetaminophen Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty: a Randomized, Blinded Trial
Actual Study Start Date : February 16, 2017
Estimated Primary Completion Date : September 16, 2018
Estimated Study Completion Date : November 16, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oral Tylenol
Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
Drug: Acetaminophen
Oral acetaminophen, intravenous placebo

Experimental: Intravenous Tylenol
Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
Drug: Acetaminophen
Intravenous acetaminophen, oral placebo




Primary Outcome Measures :
  1. Pain with physical therapy on post-operative day 1 [ Time Frame: Post operative day 1 ]
    NRS questionnaire

  2. Opioid Use [ Time Frame: Day of surgery to post-operative day 3 ]
    oral morphine equivalents, cumulative, POD 0-3. Recorded in Medication Usage Database

  3. Opioid side effects [ Time Frame: Post-operative day 1 ]
    Opioid related symptom distress scale, ORSDS, composite score POD1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Adult
  • Scheduled for an elective primary THA with a participating surgeon,
  • Planned for Combined Spinal Epidural anesthesia (CSE) and Patient Controlled Epidural Analgesia (PCEA)
  • English-speaking
  • Patients that did not receive pre-operative opioids

Exclusion criteria:

  • Hepatic or renal insufficiency, as defined by abnormal readings on liver and kidney functioning tests.
  • Hypersensitivity or contraindication to protocol medication
  • Contraindication for CSE and PCEA
  • Incapable to provide consent/answer questions in English
  • Revision or urgent surgery
  • Receiving Periarticular Injections
  • History of opioid use
  • Patients on disability or worker's compensation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03020966


Contacts
Contact: George A Birch, BS 2127747377 birchg@hss.edu
Contact: Ahava Muskat, BS 2126061510 muskata@hss.edu

Locations
United States, New York
Hospital for Special Surgery Recruiting
New York, New York, United States, 10021
Contact: George A Birch, BS    212-774-7377    birchg@hss.edu   
Contact: Ahava Muskat, BS    2126061510    muskata@hss.edu   
Principal Investigator: Jacques YaDeau, MD, PhD         
Principal Investigator: Geoffrey H Westrich, MD         
Sponsors and Collaborators
Hospital for Special Surgery, New York
Mallinckrodt
Investigators
Principal Investigator: Jacques Ya Deau, MD, PhD Hospital for Special Surgery, New York

Publications:

Responsible Party: Hospital for Special Surgery, New York
ClinicalTrials.gov Identifier: NCT03020966     History of Changes
Other Study ID Numbers: 2016-209
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: March 29, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Pain, Postoperative
Pain
Neurologic Manifestations
Nervous System Diseases
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Acetaminophen
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics